MtDNA As a Cancer Marker: A Finally Closed Chapter?

Area of Science:

• Biochemistry
• Genetics
• Oncology

Background:

• Sequence alterations in mitochondrial DNA (mtDNA) are observed across numerous tumor types.
• The exact nature of these alterations, including somatic mutations and shifts in heteroplasmic mtDNA variants, requires further elucidation.
• The high copy number of mtDNA facilitates the detection of tumor-derived aberrant DNA in bodily fluids.

Purpose of the Study:

• To review the potential of mitochondrial DNA (mtDNA) sequence alterations as a tumor marker.
• To explore the utility of mtDNA analysis for non-invasive cancer surveillance, with a focus on urinary bladder carcinoma.
• To assess the feasibility of using mtDNA analysis for sensitive follow-up of known tumor diseases.

Main Methods:

• Review of existing literature on mitochondrial DNA (mtDNA) sequence alterations in various tumor types.
• Discussion of the high copy number of mtDNA and its implications for detection in bodily fluids.
• Exploration of sequencing approaches and PCR-based assays for detecting mtDNA alterations in accessible body fluids.

Main Results:

• Mitochondrial DNA (mtDNA) alterations occur with sufficient frequency in tumors to be considered potential biomarkers.
• Urinary bladder carcinoma is a prime candidate for mtDNA-based surveillance due to cell shedding into accessible bodily fluids.
• Whole mtDNA sequencing may be intensive for initial screening, but targeted assays for deletions/insertions could be effective for surveillance.

Conclusions:

• Mitochondrial DNA (mtDNA) analysis presents a promising avenue for sensitive, non-invasive cancer follow-up, especially for urinary bladder carcinoma.
• Further investigation is warranted to determine the sensitivity of sequencing and PCR-based methods for detecting tumor-derived mtDNA in bodily fluids.
• The use of mtDNA as a biomarker for cancer surveillance warrants increased attention and research.